BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 3224088)

  • 1. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer.
    Bertelsen K; Hansen MK; Pedersen PH; Larsen G; Nyland M; Jacobsen M; Andersen JE
    Br J Obstet Gynaecol; 1988 Dec; 95(12):1231-6. PubMed ID: 3224088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
    Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
    Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of second-look laparotomy in the management of patients with stage II, III and IV ovarian cancers following chemotherapy with cisplatin, adriamycin and cyclophosphamide.
    Kirwan PH; Naftalin NJ; Khanna S; Aukett RJ
    Br J Obstet Gynaecol; 1986 Jun; 93(6):629-33. PubMed ID: 3730331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
    Bertelsen K; Jakobsen A; Strøyer J; Nielsen K; Sandberg E; Andersen JE; Ahrons S; Nyland M; Hjortkjaer Pedersen P; Larsen G
    Gynecol Oncol; 1993 Apr; 49(1):30-6. PubMed ID: 8482557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
    Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
    Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest.
    Chiara S; Lionetto R; Campora E; Oliva C; Merlini L; Bruzzi P; Rosso R; Conte PF
    Eur J Cancer; 1995; 31A(3):296-301. PubMed ID: 7786592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
    Bertelsen K; Jakobsen A; Andersen JE; Ahrons S; Pedersen PH; Kiaer H; Arffmann E; Bichel P; Boestofte E; Strøyer I
    Gynecol Oncol; 1987 Oct; 28(2):161-9. PubMed ID: 3311924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
    Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
    Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
    Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
    Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
    Omura GA; Bundy BN; Berek JS; Curry S; Delgado G; Mortel R
    J Clin Oncol; 1989 Apr; 7(4):457-65. PubMed ID: 2926470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
    J Clin Oncol; 1991 Sep; 9(9):1668-74. PubMed ID: 1831495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abdominopelvic irradiation for stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy.
    Menczer J; Modan M; Brenner J; Ben-Baruch G; Brenner H
    Gynecol Oncol; 1986 Jun; 24(2):149-54. PubMed ID: 3710262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
    Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
    Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
    Richman CM; Podczaski E; Weiser PA; Herbst AL
    Oncology; 1986; 43(1):12-7. PubMed ID: 3079898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy (CAP) for the treatment of advanced ovarian cancer and second-effort surgery in the second look.
    Ojeda-González MB; Alvárez-López I; Alonso-Muñoz MC; Badía-Serra J; Delgado-Latre E; de Andrés-Basauri L; López-López JJ
    Oncology; 1991; 48(1):7-12. PubMed ID: 1987501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation].
    Inagaki J; Ogawa M; Horikoshi N; Ezaki K; Inoue K; Aiba K; Komyo M; Miyamoto H; Ikeda K; Kubo H
    Gan No Rinsho; 1983 Aug; 29(10):1291-5. PubMed ID: 6685195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.